Last reviewed · How we verify

Metoprolol Tartrate Tablets 25 mg

Mylan Pharmaceuticals Inc · Phase 1 active Small molecule Quality 15/100

Metoprolol Tartrate Tablets 25 mg is a Small molecule drug developed by Mylan Pharmaceuticals Inc. It is currently in Phase 1 development.

At a glance

Generic nameMetoprolol Tartrate Tablets 25 mg
SponsorMylan Pharmaceuticals Inc
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Metoprolol Tartrate Tablets 25 mg

What is Metoprolol Tartrate Tablets 25 mg?

Metoprolol Tartrate Tablets 25 mg is a Small molecule drug developed by Mylan Pharmaceuticals Inc.

Who makes Metoprolol Tartrate Tablets 25 mg?

Metoprolol Tartrate Tablets 25 mg is developed by Mylan Pharmaceuticals Inc (see full Mylan Pharmaceuticals Inc pipeline at /company/mylan-pharmaceuticals-inc).

What development phase is Metoprolol Tartrate Tablets 25 mg in?

Metoprolol Tartrate Tablets 25 mg is in Phase 1.

What are the side effects of Metoprolol Tartrate Tablets 25 mg?

Common side effects of Metoprolol Tartrate Tablets 25 mg include Headache, Palpitations, Decreased appetite, Medical device site reaction, nausea, Constipation.

Related